Antitumor activity of enzastaurin as radiation sensitizer in head and neck squamous cell carcinoma

Head and Neck

Volumn 33, Issue 8, 2011, Pages 1106-1114

  Yin, Xiaoying ^a,b   Hayes, D Neil ^a,b   Shores, Carol G ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

chemoradiation; head and neck squamous cell carcinoma; PKC inhibitor; radiosensitizer; xenograft

Indexed keywords

CISPLATIN; ENZASTAURIN; RADIOSENSITIZING AGENT;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DRUG SCREENING; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL DEATH; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE C; RADIATION-SENSITIZING AGENTS; RANDOM ALLOCATION; SENSITIVITY AND SPECIFICITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960398221     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21578     Document Type: Article

References (20)

1. de Castro G Jr, Snitcovsky IM, Gebrim EM, et al. High-dose cisplatin concurrent to conventionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2007; 264: 1475-1482. (Pubitemid 350112409)
2. Adelstein DJ, Saxton JP, Lavertu P, et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: Preliminary results Head Neck 1997; 19: 567-575. (Pubitemid 27407310)
3. Carter CA,. Protein kinase C as a target: implications for drug or diet prevention and treatment of cancer. Curr Drug Targets 2000; 1: 163-183.
4. O'Brian C, Vogel VG, Singletary SE, Ward NE,. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res 1989; 49: 3215-3217. (Pubitemid 19162127)
5. Schwartz GK, Jiang J, Kelsen D, Albino AP,. Protein kinase C: a novel target for inhibiting gastric cancer cell invasion. J Natl Cancer Inst 1993; 85: 402-407. (Pubitemid 23073160)
6. Gokmen-Polar Y, Murray NR, Velasco MA, Gatalica Z, Fields AP,. Elevated protein kinase C-β II is an early promotive event in colon carcinogenesis. Cancer Res 2001; 61: 1375-1381. (Pubitemid 34292559)
7. Goekjian PG, Jirousek MR,. Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs 2001; 10: 2117-2140. (Pubitemid 34000377)
8. Valerie K, Yacoub A, Hagan M, et al. Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther 2007; 6: 789-801. (Pubitemid 46554549)
9. Balendran A, Hare GR, Kieloch A, Williams MR, Alessi DR,. Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms. FEBS Lett 2001; 484: 217-234.
10. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase C beta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005; 65: 7462-7469. (Pubitemid 41161281)
11. Querfeld C, Rizvi MA, Kuzel TM, et al. The selective protein kinase C β inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Derm 2006; 126: 1641-1647.
12. Rizvi MA, Ghias K, Davies K, et al. Enzastaurin, a protein kinase Cβ Inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther 2006; 5: 1783-1789. (Pubitemid 44323246)
13. Teicher BA, Menon K, Alvarez E, Shih C, Faul MM,. Antiangiogenic and antitumor effects of a protein kinase C β inhibitor in human breast cancer and ovarian cancer xenografts. Invest New Drugs 2002; 20: 241-251. (Pubitemid 34823752)
14. Tabatabai G, Frank B, Wick A, et al. Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann Neurol 2007; 61: 153-161. (Pubitemid 46363842)
15. Dudek AZ, Zwolak P, Jasinski P, et al. Protein kinase C-β inhibitor enzastaurin enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis. Invest New Drugs 2008; 26: 13-24.
16. Baumann P, Armann J, Mandl-Weber S, Grün G, Oduncu F, Schmidaier R,. Inhibitors of protein kinase K sensitise multiple myeloma cells to common genotoxic drugs. Eur J Haematol 2007; 80: 37-45.
17. Hanauske A, Oberschmidt O, Hanauske-Abel H, Lahn M, Eismann U,. Antitumor activity of enzastaurin against human cancer cell lines and freshly explanted tumors investigated in vitro soft-agar cloning experiment. Invest New Drugs 2007; 25: 205-210. (Pubitemid 46774707)
18. Jasinski P, Terai K, Zwolak P, Dudek A,. Enzastaurin renders MCF-7 breast cancer cells sensitive to radiation through reversal of radiation-induced activation of protein kinase C. Eur J Cancer 2008; 44: 1315-1322.
19. Spalding A, Watson R, Davis M, Kim A, Lawrence T, Ben-Josef E, Inhibition of protein C β by enzastaurin enhances radiation cytotoxicity in pancreatic cancer. Clin Cancer Res 2007; 13: 6827-6833. (Pubitemid 350206821)
20. Teicher BA, Alvarez E, Menon K, et al. Antiangiogenic effects of a protein kinase C Aß-selective small molecule. Cancer Chemother Pharmacol 2002; 49: 69-77.